Vaccine News and Research

Latest Vaccine News and Research

New dengue virus serotype DENV3 has re-emerged in Singapore after three decades

Dengue infections are rising, even as public health authorities are battling to contain the spread of the coronavirus. Dengue virus serotype 2 (DENV2) had previously been the predominant serotype but DENV3 has re-emerged in Singapore after almost three decades.

23 Jun 2020

Antibodies against prevalent endemic human coronaviruses may provide cross-protection to SARS-CoV-2

Researchers from Qatar have demonstrated that antibody repertoires against endemic human coronaviruses are qualitatively different in children when compared to the general adult population, as well as healthy adult blood bank donors – and they may also provide cross-protection against epidemic/pandemic strains.

23 Jun 2020

First clinical trial in South Africa for Covid-19 vaccine begins

The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

23 Jun 2020

Is a second wave of coronavirus coming?

As Americans continue to grapple with the novel coronavirus, one question is on a lot of people's minds: Are we already seeing, or will we eventually see, a second wave of the virus?

23 Jun 2020

White Paper: Separation and characterization of viruses and antibodies

Postnova Analytics have published an informative new white paper that details how multi-detector Asymmetrical Field Flow Fractionation (AF4) and Electrical AF4 (EAF4) techniques are transforming the separation and characterization of viruses and antibodies.

From Postnova Analytics 23 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020

Scientists create 'all-atom' model of SARS-CoV-2 spike protein

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease (COVID-19), an illness that has spread across the globe, infecting more than 9 million people. The novel coronavirus invades cells through "spike proteins," which sticks and binds itself to a host cell.

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Cardiac care in the era of COVID-19

As Cedars-Sinai expands telehealth and video visits and resumes surgeries, Joanna Chikwe, MD, chair of the Department of Cardiac Surgery at the Smidt Heart Institute, has her focus on one thing: ensuring that patients with heart disease understand it is safe to be seen, and treated, by Cedars-Sinai healthcare teams.

22 Jun 2020

Three vaccine candidates race to combat SARS-CoV-2

As the coronavirus disease (COVID-19) ravages across the globe, scientists are racing to develop an effective vaccine to combat the viral infection. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease has infected nearly 9 million people.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

The role of brain cells in spreading HIV

Dr. Lena Al-Harthi speaks to News-Medical about her research into HIV treatment and the role of brain cells in spreading the HIV virus.

22 Jun 2020

Tumor cell–based vaccine may prevent relapse of mantle cell lymphoma

A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment.

22 Jun 2020

Researchers produce first fully-glycosylated full-length SARS-CoV-2 spike protein models

The virus SARS coronavirus 2 (SARS-CoV-2) is the known cause of coronavirus disease 2019 (COVID-19). The "spike" or S protein facilitates viral entry into host cells.

22 Jun 2020

Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccine

Ligandal, one of the world’s leading genetic medicine companies, has modeled a synthetic peptide that could be an effective COVID-19 treatment and SARS-CoV-2 vaccine.

22 Jun 2020

A highly sensitive and specific antibody test for COVID-19

A new proof-of-concept study by UK researchers, currently available on the medRxiv* preprint server, describes the development of an enzyme-linked immunosorbent assay that can be used when lower levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific-antibodies are present in serum and saliva samples.

21 Jun 2020

Research explores the biophysical behavior of SARS-CoV-2 nucleocapsid protein

In a groundbreaking paper currently available on the bioRxiv* preprint server, the researchers from the Washington University School of Medicine and Stony Brook University showed how nucleocapsid protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is dynamic, disordered and phase separates with RNA – informing, in turn, the discovery of drugs that disrupt viral packaging.

21 Jun 2020